Ubs Group Ag Dyne Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 121,792 shares of DYN stock, worth $1.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

121,792

Previous 357,754 65.96%

Holding current value

$1.77 Million

Previous $3.74 Million 69.03%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.81 - $14.78 $1.61 Million - $3.49 Million	-235,962 Reduced 65.96%	121,792 $1.16 Million
Q1 2025 May 13, 2025	SELL	$10.46 - $25.46 $1.91 Million - $4.64 Million	-182,358 Reduced 33.76%	357,754 $3.74 Million
Q4 2024 Feb 14, 2025	SELL	$23.56 - $35.55 $2.02 Million - $3.04 Million	-85,607 Reduced 13.68%	540,112 $12.7 Million
Q3 2024 Nov 14, 2024	BUY	$31.94 - $47.04 $12.2 Million - $18 Million	381,790 Added 156.52%	625,719 $22.5 Million
Q2 2024 Aug 13, 2024	BUY	$23.65 - $35.63 $250,737 - $377,749	10,602 Added 4.54%	243,929 $8.61 Million
Q1 2024 May 13, 2024	BUY	$13.06 - $29.18 $1.43 Million - $3.19 Million	109,277 Added 88.09%	233,327 $6.62 Million
Q4 2023 Feb 09, 2024	BUY	$6.62 - $13.64 $462,685 - $953,326	69,892 Added 129.05%	124,050 $1.65 Million
Q3 2023 Nov 09, 2023	BUY	$8.6 - $12.18 $271,665 - $384,754	31,589 Added 139.97%	54,158 $485,000
Q2 2023 Aug 11, 2023	BUY	$8.53 - $14.28 $180,153 - $301,593	21,120 Added 1457.56%	22,569 $253,000
Q1 2023 May 12, 2023	SELL	$10.88 - $15.0 $88,421 - $121,905	-8,127 Reduced 84.87%	1,449 $16,000
Q4 2022 Feb 08, 2023	BUY	$9.37 - $13.8 $79,926 - $117,714	8,530 Added 815.49%	9,576 $110,000
Q3 2022 Nov 10, 2022	BUY	$7.2 - $15.17 $115 - $242	16 Added 1.55%	1,046 $13,000
Q2 2022 Aug 10, 2022	SELL	$4.36 - $10.5 $39,859 - $95,991	-9,142 Reduced 89.87%	1,030 $7,000
Q1 2022 May 16, 2022	BUY	$6.52 - $12.27 $63,635 - $119,755	9,760 Added 2368.93%	10,172 $98,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $16.07 $4,601 - $6,219	387 Added 1548.0%	412 $5,000
Q3 2021 Nov 15, 2021	BUY	$15.6 - $21.46 $390 - $536	25 New	25 $0
Q2 2021 Aug 13, 2021	SELL	$15.94 - $22.33 $52,251 - $73,197	-3,278 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$14.0 - $29.3 $93,548 - $195,782	-6,682 Reduced 67.09%	3,278 $51,000
Q4 2020 Feb 11, 2021	BUY	$16.81 - $23.94 $167,427 - $238,442	9,960 New	9,960 $209,000

Others Institutions Holding DYN

# of Institutions

211

Shares Held

122M

Call Options Held

36.5K

Put Options Held

74.3K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $754M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account